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SCIENTIFIC OPINION 
Scientific Opinion on the safety and efficacy of zinc chelate of  
L-lysinate-HCl as feed additive for all animal species
1
 
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT 
Zinc chelate of L-lysinate-HCl for all animal species, provided as powder and granulate, is intended for use as 
zinc compound in animal nutrition. Tolerance studies with calves and weaned piglets allowed the Panel on 
Additives and Products or Substances used in Animal Feed (FEEDAP) to conclude that zinc chelate of  
L-lysinate-HCl is a safe source of zinc for all animal species, provided that the maximum zinc contents 
authorised in complete feed are respected. The supplementation of feeds with zinc from zinc chelate of  
L-lysinate-HCl up to the maximum authorised zinc levels is not expected to result in a different zinc deposition 
in edible tissues/products than the standard inorganic source zinc sulphate heptahydrate. No concerns for 
consumer safety will arise from the use of the additive in animal nutrition. Zinc chelate of L-lysinate-HCl in the 
powder form poses a risk to users by inhalation, whilst for the granulate form that risk is minimised. Neither 
form, powder or granulate, is a dermal irritant; however, both forms are irritant to the eye. In the absence of 
specific information, the additive should be regarded as a potential skin sensitiser. Zinc chelate of L-lysinate-HCl 
is intended to be a substitute for other authorised zinc additives. It will therefore not further increase the 
environmental burden of zinc. Based on a study on weaned piglets, the FEEDAP Panel concluded that zinc 
chelate of L-lysinate-HCl is efficacious as a source of zinc in meeting the requirements of all animal species. The 
Panel made some recommendations regarding the Description and Conditions of use of the additive. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following a request from the European Commission, the Panel on Additives and Products or 
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and 
efficacy of zinc chelate of L-lysinate-HCl for all animal species. The additive is intended to be 
marketed in two forms, powder and granules. 
Tolerance studies with calves and weaned piglets allowed the FEEDAP Panel to conclude that zinc 
chelate of L-lysinate-HCl does not elicit additional or different adverse effects compared with the 
standard inorganic source zinc sulphate heptahydrate; therefore, the additive is a safe source of zinc 
for all animal species, provided that the maximum zinc contents authorised in complete feed are 
respected. 
The supplementation of feeds with zinc from zinc chelate of L-lysinate-HCl up to the maximum 
authorised zinc levels is not expected to result in a different zinc deposition in edible tissues/products 
than the standard inorganic source zinc sulphate heptahydrate. No concerns for consumer safety will 
arise from the use of the additive in animal nutrition. 
Zinc chelate of L-lysinate-HCl in the powder form poses a risk to users by inhalation, whilst for the 
granulate form that risk is minimised. Neither form, powder or as granulate, is a dermal irritant. Both 
forms are irritant to the eye. In the absence of specific information, the additive should be regarded as 
a potential skin sensitiser. 
The additive under assessment, zinc chelate of L-lysinate-HCl, is intended to be a substitute for other 
authorised zinc additives. It will therefore not further increase the environmental burden of zinc. 
Based on a study on weaned piglets, the FEEDAP Panel concluded that zinc chelate of L-lysinate-HCl 
is efficacious as a source of zinc in meeting the requirements of all animal species. 
The Panel made some recommendations regarding the Description and Conditions of use of the 
additive. 
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BACKGROUND 
Regulation (EC) No 1831/2003
4
 establishes the rules governing the Community authorisation of 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an 
application in accordance with Article 7. 
The European Commission received a request from the company Senzyme GmbH
5
 for authorisation of 
the product zinc chelate of L-lysinate-HCl, when used as a feed additive for all animal species 
(category: Nutritional additives; functional group: compounds of trace elements) under the conditions 
mentioned in Table 1. 
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the 
application to the European Food Safety Authority (EFSA) as an application under Article 4(1) 
(authorisation of a feed additive or new use of a feed additive). EFSA received directly from the 
applicant the technical dossier in support of this application.
6
 According to Article 8 of that 
Regulation, EFSA, after verifying the particulars and documents submitted by the applicant, shall 
undertake an assessment in order to determine whether the feed additive complies with the conditions 
laid down in Article 5. The particulars and documents in support of the application were considered 
valid by EFSA as of 16 September 2014. 
The feed additive zinc chelate of L-lysinate-HCl has not been previously authorised in the European 
Union (EU). Other zinc compounds are authorised to be used as nutritional feed additives (trace 
elements) in the EU by Commission Regulation (EC) No 1334/2003,
7
 Commission Regulation (EC) 
No 479/2006,
8
 Commission Regulation (EC) No 888/2009,
9
 Commission Regulation (EU) No 
335/2010,
10
 Commission Implementing Regulation (EU) No 991/2012
11
 and Commission 
implementing Regulation (EU) No 636/2013.
12
 
The Scientific Committee on Animal Nutrition (SCAN) issued an opinion on the use of zinc in 
feedingstuffs (EC, 2003a). EFSA issued opinions on the safety of the chelated forms of iron, copper, 
manganese and zinc with synthetic feed grade glycine (EFSA, 2005), on the safety and efficacy of a 
zinc chelate of hydroxy analogue of methionine (Mintrex®Zn) (EFSA, 2008, 2009a, 2009b), of tetra-
basic zinc chloride (EFSA, 2012a) and of methionine-zinc (EFSA FEEDAP Panel, 2013a) as feed 
additives (compounds of trace elements). In the frame of re-evaluation, EFSA has delivered seven 
opinions: zinc chelate of amino acids hydrate (EFSA, 2012b; EFSA FEEDAP Panel, 2013b), zinc 
sulphate monohydrate (EFSA 2012c, 2012d), zinc oxide (EFSA, 2012e) and of seven zinc compounds 
(zinc acetate, dihydrate; zinc chloride, anhydrous; zinc oxide; zinc sulphate, heptahydrate; zinc 
sulphate, monohydrate; zinc chelate of amino acids, hydrate; zinc chelate of glycine, hydrate (EFSA 
FEEDAP Panel, 2015). 
                                                     
4 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use 
in animal nutrition. OJ L 268, 18.10.2003, p. 29. 
5 Senzyme GmbH, Gierlichsstraße, 6. 53840 Troisdorf , Germany. 
6 EFSA Dossier reference: FAD-2014-0021. 
7 Commission Regulation (EC) No 1334/2003 amending the conditions for authorisation of a number of additives in 
feedingstuffs belonging to the group of trace elements. OJ L 187, 26.7.2003, p. 11. 
8 Commission Regulation (EC) No 479/2006 as regards the authorisation of certain additives belonging to the group 
compounds of trace elements. OJ L 86, 24.3.2006, p. 4. 
9 Commission Regulation (EC) No 888/2009 concerning the authorisation of Zinc chelate of hydroxy analogue of 
methionine as a feed additive for chickens for fattening. OJ L 254, 26.9.2009, p. 71. 
10 Commission Regulation (EU) No 335/2010 of 22 April 2010 concerning the authorisation of zinc chelate of hydroxy 
analogue of methionine as a feed additive for all animal species. OJ L 102, 23.4.2010, p. 22. 
11 Commission Implementing Regulation (EU) No 991/2012 of 25 October 2012 concerning the authorisation of zinc 
chloride hydroxide monohydrate as feed additive for all animal species. OJ L 297, 26.10.2012, p. 18. 
12 Commission Implementing Regulation (EU) No 636/2013 concerning the authorisation of zinc chelate of methionine (1:2) 
as a feed additive for all animal species. OJ L 183, 2.7.2013, p. 3. 
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EFSA has issued an opinion on the potential reduction of the currently authorised maximum zinc 
content in complete feed. The newly proposed maximum contents are: 150 mg Zn/kg complete feed 
for piglets, sows, rabbits, salmonids, cats and dogs; 120 mg Zn/kg complete feed for turkeys for 
fattening; 100 mg Zn/kg complete feed for all other species and categories (EFSA FEEDAP Panel, 
2014). 
TERMS OF REFERENCE 
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the 
safety for the target animals, consumer, user and the environment and the efficacy of zinc chelate of L-
lysinate-HCl, when used under the conditions described in Table 1. 
Table 1:  Description and conditions of use of the additive as proposed by the applicant  
Additive  Zinc chelate of L-Lysinate HCl (Aminotrace Zinc Bislysinate) 
Registration number/EC 
No/No (if appropriate) 
- 
Category(-ies) of additive nutritional additive, 3 
Functional group(s) of additive compounds of trace elements, b 
 
Description 
Composition, description 
Chemical formula Purity criteria 
(if appropriate) 
Method of analysis 
(if appropriate) 
Zinc chelate from 
L-Lysinate HCl 
Zn(C6H13N2O2)2 x 2HCl 
in compliance with EU 
legislation 
EN 15510:2007 
(zinc) 
VDLUFA 4.11.6 
(L-Lysinate HCl) 
 
Trade name (if appropriate) n.a. 
Name of the holder of 
authorisation (if appropriate) 
n.a. 
 
Conditions of use 
Species or 
category of animal 
Maximum 
Age 
Minimum content Maximum content Withdrawal 
period 
(if appropriate) mg/kg of complete feedingstuffs 
All animal species - - 
according Commission 
Regulation (EC) 
1334/2003 
n.a. 
 
Other provisions and additional requirements for the labeling 
Specific conditions or restrictions for 
use (if appropriate) 
Feed formulation should be adjusted to account for the lysine 
activity of L-Lysinate HCl. 
Specific conditions or restrictions for 
handling (if appropriate) 
For user safety: use safety glasses and protective gloves. In case of 
dust formation take appropriate measures for breathing protection. 
The precautions for handling on the safety data sheet must be 
observed. 
Post-market monitoring 
(if appropriate) 
Senzyme GmbH will conduct post-marketing monitoring in 
compliance with EU law on feed hygiene, namely by use of HACCP 
and Traceability systems and formal monitoring of customer 
feedback through product or service complaints. 
Aminotrace zinc bislysinate for all animal species 
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Specific conditions for use in 
complementary feedingstuffs 
(if appropriate) 
To supply zinc in final feeds within EU legal limits for each species 
 
Maximum Residue Limit (MRL) (if appropriate) 
Marker residue 
Species or category of 
animal 
Target tissue(s) or 
food products 
Maximum content in 
tissues 
n.a. n.a. n.a. n.a. 
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ASSESSMENT 
1. Introduction 
The transition metal zinc is essential to all living organisms. It is an integral component of an 
estimated 10 % of all proteins, in which it contributes to tertiary structure or catalytic activity covering 
all enzyme classes. It is also a signalling substance in its functions as second messenger and as 
synaptic neuromodulator. The biological functions of zinc are numerous and diverse and include 
glucose and lipid metabolism, cell proliferation, embryogenesis and those related to the nervous and 
immune systems. The roles of zinc, its deficiency and toxicity symptoms in farm animals have been 
described in previous opinions of the Scientific Committee on Animal Nutrition (EC, 2003a) and the 
European Food Safety Authority Panel on Additives and Products or Substances used in Animal Feed 
(EFSA FEEDAP Panel, 2014, 2015). To the knowledge of the FEEDAP Panel, there is no additional 
relevant information that may lead to reconsideration of these opinions. 
The applicant is seeking authorisation for the use of zinc chelate of L-lysinate-HCl in feed for all 
animal species/categories. This zinc compound is not currently authorised in the EU as a feed additive. 
2. Characterisation 
For compounds of trace elements, the element itself is considered the active substance. 
2.1. Characterisation of zinc chelate of L-lysinate-HCl 
A Chemical Abstracts Service (CAS) or the International Union of Pure and Applied Chemistry 
(IUPAC) name could not be identified for the additive under assessment, zinc chelate of L-lysinate-
HCl.
13
 However, for the zinc lysine complex without the HCl, the CAS number is 23333-98-4 and the 
IUPAC name is zinc bislysinate chelate. The chemical formula of the additive is 
Zn(C6H13N2O2)2 × 2HCl × 2H2O and the molecular mass 464.72 Da.
14
 The theoretical content of zinc 
is 14.07 %. 
The additive is intended to be marketed in two forms: powder, containing the additive as such, and 
granulate, with an admixture of approximately 0.5 % binding agents (e.g. carboxymethylcellulose). 
Both forms of the additive are specified to contain ≥ 13.7 % zinc and ≤ 86.3 % L-lysine HCl. The 
analysis of five batches of each form was submitted. Average values for the powder were 13.9 ± 0.2 % 
Zn and 85.6 ± 0.3 % lysine HCl15 and for the granulate were 14.0 ± 0.2 % Zn and 85.6 ± 0.2 % lysine 
HCl.16 Infrared absorbance data and elemental analysis of water-soluble and -insoluble material 
indicate that the additive consists of > 85 % of zinc chelate of L-lysinate-HCl. The remaining 15 % is 
zinc oxide which does not react with L-lysine during the synthesis process.
17
 
The chemical structure of zinc chelate of L-lysinate-HCl is shown in Figure 1. 
                                                     
13 Other names: Zinc, bis(L-lysinato-KN2, KO1)-, (T-4)-bis-hydrochloride. 
14 Technical Dossier/Supplementary Information April 2015/Annex 1. 
15 Technical Dossier/Section II/Annex II_1_2. 
16 Technical Dossier/Section II/Annex II_1_3. 
17 Technical Dossier/Supplementary Information April 2015/Annex 1. 
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Figure 1:  Chemical structure of crystallised zinc chelate of L-lysinate-HCl according to Cambridge 
Crystallographic Data Centre under CCDC No 1048236. 
Heavy metals (cadmium, lead, mercury), fluorine, arsenic, dioxins and dioxin-like polychlorinated 
biphenyls (PCBs) were analysed in three batches of the powder form.
18
 Reported values were below 
the detection limits for arsenic (5 mg/kg), lead (10 mg/kg), cadmium (1 mg/kg), mercury (0.1 mg/kg) 
and fluorine (25 mg/kg) and below the thresholds of the Directive on undesirable substances for 
dioxins and dioxin-like PCBs.
19
 
2.1.1. Physical state of the product 
The product is white-grey in colour, has an unobtrusive odour and comes in two forms: solid free-
flowing powder and granulate. The relative and the compressed densities for the powder are 500 and 
580 kg/m
3
, respectively.
20
 For the granulate form of the additive, the corresponding values are 480 and 
550 kg/m
3
.
21
 The water solubility of both forms of the additive is 0.5 g/L. 
Mean particle size of the powder form was determined in three batches and ranged from 46 to 
49 μm.22 The samples contain 1518 % (v/v) of particulate matter with particle sizes < 10 μm; the dust 
contains 9597 % particles < 10 μm. The granulate form has a mean particle size of 589595 µm with 
virtually no particles below 10 µm.
23
 The dusting potential of the powder form as measured by the 
Stauber-Heubach method was 12.813.5 g/m3,24 whereas the value found for the granulate was below 
the detection limit (0.1 mg/m
3
).
25
 
2.2. Manufacturing process 
The manufacturing process is fully described in the technical dossier. The starting raw materials used 
for the production of the additive are zinc oxide and L-lysine HCl. The lysine source used is produced 
by fermentation with the genetically modified strain FERM BP-10941 of Escherichia coli; the safety 
of this lysine source has already been assessed by the FEEDAP Panel (EFSA FEEDAP Panel, 2013b). 
The material safety data sheets of the raw materials L-lysine,
26
 zinc oxide
27
 and 
carboxymethylcellulose
28
 were provided. 
                                                     
18 Technical Dossier/Section II/Annex II_1_4. 
19 Directive 2002/32/EC of the European Parliament and of the Council of 7 May 2002 on undesirable substances in animal 
feed. OJ L 140, 30.5.2002, p. 10. 
20 Technical Dossier/Section II/Annex II_1_5.  
21 Technical Dossier/Section II/Annex II_1_8.  
22 Technical Dossier/Section II/Annex II_1_6.  
23 Technical Dossier/Section II/Annex II_1_9.  
24 Technical Dossier/Section II/Annex II_1_7.  
25 Technical Dossier/Section II/Annex II_1_10.  
26 Technical Dossier/Section II/Annex II_3_4.  
27 Technical Dossier/Section II/Annex II_3_6.  
28 Technical Dossier/Section II/Annex II_3_8.  
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2.3. Stability and homogeneity 
Stability data of the additive were not provided by the applicant and are generally not required for 
compounds of trace elements. A minimum shelf life of one year is proposed by the applicant. 
The capacity of both forms of the additive to homogeneously distribute was presented in studies 
conducted with a premixture for sows and with a variety of compound feedingstuffs (composition not 
provided).
29
 Based on the analysed zinc concentration (total minus background), the coefficients of 
variation were similar for the powder and granulate forms and ranged from 0.34 to 0.36 % in the 
premixture and from 0.21 to 3.12 % in compound feed. 
2.4. Physico-chemical incompatibilities in feed 
According to the current knowledge, no incompatibilities or adverse interactions with feed 
components, carriers, other approved additives or medicinal products are to be expected other than 
those widely recognised for zinc in animal nutrition. 
2.5. Conditions of use 
The zinc compound under application, zinc chelate of L-lysinate-HCl, is intended to supply zinc in 
final feed for all animal species/categories up to a maximum total content in complete feedingstuffs of 
250 mg Zn/kg for pet animals, 200 mg Zn/kg for fish and for milk replacers and 150 mg Zn/kg for 
other species. 
2.6. Evaluation of the analytical methods by the European Union Reference Laboratory 
(EURL) 
EFSA has verified the EURL report as it relates to the methods used for the control of zinc chelate of 
L-lysinate-HCl in animal feed. The Executive Summary of the EURL report can be found in the 
Annex. 
3. Safety 
3.1. Safety for the target species 
3.1.1. Tolerance studies for the target species 
3.1.1.1. Tolerance study in calves 
A 6-week experiment with 60 Friesian bull calves was not considered because the intended dietary 
zinc concentrations were not analytically confirmed and the doses tested did not allow to establish a 
margin of safety.
30
 
Another 6-week trial was carried out with 60 Friesian bull calves (initial age 21 days, average body 
weight 53 kg).
31
 For each of the four treatments, 15 calves were housed together in one pen and 
individually fed milk replacer by automatic feeders. Hay was available for ad libitum intake. The basal 
diet (milk replacer; background zinc: 28 mg/kg feed) was supplemented with zinc sulphate 
heptahydrate or zinc chelate of L-lysinate-HCl to obtain the intended concentration of 40 and 500 mg 
Zn/kg diet (2.5 fold maximum content of total zinc). The zinc concentrations in the diets were 
confirmed by analysis. Animals were medicated for the first ten days prophylactically against 
respiratory diseases and diarrhoea and were vaccinated twice against the bovine respiratory syncytial 
virus and treated against endo- and ectoparasites. The animals were weighed weekly; feed intake was 
recorded daily. At the end of the trial, blood samples were taken from four calves per treatment for 
                                                     
29 Technical Dossier/Section II/Annex II_4_1 (powder form) and Annex II_4_2 (granulate form).  
30 Technical Dossier/Section III/Annex III_1_1. 
31 Technical Dossier/Section III/Annex III_1_2. 
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haematology
32
 and clinical chemistry.
33
 Statistical analysis included tests on homogeneous distribution 
and variance homogeneity; depending on the outcome, analysis of variance (ANOVA) followed by a 
post-hoc test or non-parametric test were used (statistical package SPSS 21). These data on 
zootechnical and selected haematology parameters are summarised in Table 2. 
Table 2:  Effect of level and source of zinc in milk replacer (MR) on performance and on some 
haematological parameters in calves (initial body weight: 53.0 kg; duration of study: 42 days) 
Zinc source Zinc sulphate Zinc lysinate Zinc sulphate Zinc lysinate 
Intended Zn (mg/kg MR) 40 500 
Analysed Zn (mg/kg MR) 50 49 534 527 
MR intake (kg/calf per day) 0.99 1.00 0.96 0.98 
Hay intake (kg/calf per day) 0.27 0.28 0.27 0.27 
Daily weight gain (g) 706 741 685 752 
Final body weight (kg) 82.5 84.0 82.0 85.1 
Haematocrit (%) 32.3
ac
 33.4
a
 21.3
b
 26.0
bc
 
Erythrocytes (T/L) 10.5
a
 11.2
a
 7.3
b
 8.7
b
 
Haemoglobin (g/dL) 10.2
ab
 10.5
a
 8.7
b
 9.4
a
 
MCH 
(1) 
(pg) 9.7
a
 9.4
a
 11.9
b
 10.9
ab
 
MCHC 
(2)
 (g/dL) 31.7
a
 31.4
a
 41.0
c
 36.5
b
 
(1): Mean corpuscular haemoglobin. 
(2): Mean corpuscular haemoglobin concentration. 
Performance parameters: 15 animals/treatment. 
Haematology parameters: 4 animals/treatment. 
a,b,c: Different superscripts within a row indicate statistical differences (P ≤ 0.05). 
 
No mortality was observed. No significant differences in performance parameters were seen. 
Haematology parameters appeared to indicate an adverse effect of the high zinc concentration on iron 
utilisation as shown by reduced haematocrit (23.7 vs. 32.8 %), number of erythrocytes (8.0 vs. 
10.9 T/L) and haemoglobin (9.1 vs. 10.4 g/dL). It is noted that this effect was less pronounced, if any, 
at the high dose of zinc chelate of L-lysinate-HCl group (Table 2). 
This study indicates that zinc chelate of L-lysinate-HCl was equally tolerated as zinc sulphate up to 
2.5-fold the maximum authorised total zinc in milk replacer. An uncertainty results from the small 
number of animals tested for haematology and clinical chemistry parameters. It is noted that the 
feeding regime is considered untypical since no concentrate has been provided. 
3.1.1.2. Tolerance study in chickens for fattening 
A 35-day combined tolerance/efficacy study was performed in three consecutive experiments with 
chickens for fattening.
34
 
Owing to the weaknesses of the study design, the inaccuracies in reporting and controversial and 
unexplainable findings (e.g. a remarkable depression of feed intake and body weight in the treatments 
with zinc sulphate in all the doses tested within the tolerable maximum levels; the unexpected content 
of lysine, mainly in the grower diet as compared with the starter diet; the absence of response in the 
pancreas to the increasing zinc in diet), the study could not be considered in the safety assessment of 
zinc chelate of L-lysinate-HCl for chickens for fattening. 
                                                     
32 Haematocrit, erythrocytes, haemoglobin, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular 
haemoglobin concentration, leucocytes, platelets.  
33 Total proteins, albumin, aspartate aminotransferase, gamma-glutamyltransferase, urea. 
34 Technical Dossier/Section III/Annex III_1_4. 
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3.1.1.3. Tolerance study in piglets 
A 42-day combined tolerance/efficacy study was performed with 72 weaned piglets (castrated males 
and females; Euroc  Piétrain; age 25 days, average initial body weight: 6.0 kg).35 The piglets were 
allocated according to weight and sex to six dietary treatments (four replicates per treatment, three 
animals per replicate). The basal diet (wheat, barley, soybean meal and maize; background zinc 
concentration: 30‒35 mg/kg feed) was supplemented with zinc from either zinc sulphate heptahydrate 
or from zinc chelate of L-lysinate-HCl to obtain the intended doses of zinc being 80, 150 (maximum 
zinc in feed authorised in the EC) and 450 (3-fold maximum authorised in the EC) mg total Zn/kg 
feed, as confirmed by analysis. The starter diet was fed for two weeks followed by a grower diet until 
completion of the study. Body weight and feed intake (FI) per pen were recorded weekly. At the end 
of the study, blood samples were taken from all animals for haematology
36
 and clinical chemistry.
37
 
Zinc in plasma, liver, pancreas spleen, kidney and tibia was analysed from six animals per treatment. 
ANOVA was performed, followed by a Tukey post-hoc test. The test for the performance parameters 
was carried out with the pen as an experimental unit and for other parameters on the number of 
animals. The main results are presented in Table 3. 
Table 3:  Effect of level and source of zinc on performance and zinc content in different organs of 
piglets 
Zinc source  Zinc 
sulphate 
Zinc 
lysinate 
Zinc 
sulphate 
Zinc 
lysinate 
Zinc 
sulphate 
Zinc 
lysinate 
Zinc (mg Zn/kg feed) 
Supplemented 80 150 450 
Total analysed  105/113 
(1)
 114/116 185/188 192/195 497/486 497/504 
Feed intake (kg/animal) 
(2)
 24.2 24.3 24.6 24.7 25.0 25.1 
Final body weight (kg) 
(2)
 22.8 23.5 23.5 24.4 24.3 24.9 
Average daily gain (g) 
(2)
 401
a
 417
ab
 418
ab
 440
b
 436
b
 450
b
 
Feed/gain ratio 
(2)
  1.44
b
 1.39
ab
 1.40
ab
 1.34
ab
 1.37
ab
 1.33
a
 
Zinc (mg/kg DM) 
(3)
 
Liver 116.1
a
 117.5
a
 128.4
a
 132.8
a
 163.0
b
 154.5
b
 
Kidney 81.1
a
 82.8
ab
 92.1
bc
 94.5
bc
 97.4
bc
 100.6
c
 
Pancreas  66.8
a
 67.2
a
 74.2
ab
 86.1
bc
 95.1
c
 90.3
c
 
Tibia 
(4)
  123.3
ab
 114.2
a
 132.7
abc
 126.7
abc
 142.3
bc
 148.5
c
 
Zinc in plasma (mg/L) 
(5)
 1.2 1.3 1.3 1.3 1.3 1.3 
(1): Starter/grower. 
(2): Means based on n = 4 (pens with three animals/pen). 
(3): Means based on n = 6 (animals/treatment). 
(4): For tibia: mg/kg fat-free DM. 
(5): Means based on n = 12 (animals/treatment). 
a,b,c: different superscripts within a row indicate statistical differences (P ≤ 0.05). 
DM, dry matter. 
 
No mortality was observed. No significant effects were found for final body weight due to zinc source 
or level of supplementation. Average daily gain and feed/gain ratio showed an increasing and 
decreasing trend, respectively, with increasing dietary zinc levels. Significant differences in body 
weight gain were present between the low zinc sulphate group and the groups with high zinc from 
sulphate and intermediate and high zinc from lysinate; significant differences in feed/gain ratio were 
observed only between low zinc from sulphate and high zinc from lysinate. No differences were seen 
in the haematological and clinical chemistry endpoints. 
                                                     
35 Technical Dossier/Section III/Annex III_1_5. 
36 Erythrocytes, total and differential leucocytes, haematocrit, haemoglobin, mean corpuscular volume, mean corpuscular 
haemoglobinand mean corpuscular haemoglobin concentration. 
37 Electrolytes (sodium, potassium, chlorine, calcium, phosphorus), total cholesterol, triglycerides, bilirubin, urea, glucose, 
albumins, total protein, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase. 
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Zinc deposition data for liver, kidney, pancreas and tibia appeared associated to the dietary zinc 
supply; these differences became statistically significant for comparison of the low and high zinc 
groups (Table 3). There were no significant differences in the zinc deposition in those four tissues 
between the two zinc sources (sulphate and lysinate). 
The results of the study indicate that zinc chelate of L-lysinate-HCl was equally tolerated as zinc 
sulphate, by piglets up to 3-fold of the maximum authorised total zinc in complete feed for this animal 
category. 
3.1.2. Conclusions on the safety for the target species 
The FEEDAP Panel concludes on the basis of tolerance studies with calves and weaned piglets that 
zinc chelate of L-lysinate-HCl does not elicit additional or different adverse effects compared with the 
standard inorganic source zinc sulphate heptahydrate. Therefore, the FEEDAP Panel considers zinc 
chelate of L-lysinate-HCl as a safe source of zinc for all animal species, provided that the maximum 
zinc contents authorised in complete feed are respected. 
3.2. Safety for the consumer 
The metabolic behaviour of zinc was discussed in detail by the Scientific Committee on Food (SCF) 
(EC, 2003b) and, more recently, by the FEEDAP Panel (EFSA FEEDAP Panel, 2014). 
3.2.1. Metabolic and residue studies 
Potential differences in the deposition from different sources of a trace element among tissues and 
other products used for human consumption are subject of assessment of consumer safety, particularly 
for its new organic sources. 
The only available data for tissue deposition of zinc from the product under application could be 
derived from the combined tolerance/efficacy study on piglets (see section 3.1.1.3), since results from 
the study on chickens for fattening could not considered due to several deficiencies already mentioned 
in section 3.1.1.2. Concerning edible tissues, liver and kidney from piglets did not show any 
significant difference in zinc deposition between zinc sulphate, as standard authorised inorganic 
source, and zinc chelate of L-lysinate-HCl when supplemented to feed up to 450 mg Zn/kg (Table 3). 
In addition, no differences in response to dietary zinc supplementation from the two sources were 
observed in the piglet study concerning the deposition in further investigated tissues (pancreas, tibia) 
and the plasma zinc levels. 
Data from the review by Jongbloed et al. (2002) show the mean bioavailability of zinc from an 
unspecified source of zinc lysinate relative to that of zinc from zinc sulphate for pigs (based on bone 
and serum zinc) and ruminants (based on liver and kidney) to be 89 and 107 %, respectively. 
Considering also the published scientific literature, the FEEDAP Panel reiterates its recent statement 
(EFSA FEEDAP Panel, 2015) that intestinal zinc absorption is saturable, and the rate of zinc uptake is 
inversely proportional to intake within its large range of homeostatic regulation. As stated in an 
opinion of the FEEDAP Panel (EFSA FEEDAP Panel, 2014), “with the exceptions of liver and kidney 
(Eisemann et al., 1979; Jenkins and Hidiroglou, 1991; Cao et al., 2000; Gallaher et al., 2000; Wright 
and Spears, 2004; NRC, 2005; see also review of Schlegel et al., 2013), zinc concentrations exceeding 
the requirements up to about 200 mg/kg feed will not result in a change of zinc concentrations in 
animal tissues and other products including milk (Schwarz and Kirchgessner, 1975; Miller et al., 
1989; Wiking et al., 2008; Peters and Mahan, 2008; Peters et al., 2010)”. In general, there is no 
evidence in published literature that organic forms of zinc result in different levels of zinc deposition 
in muscle, egg or milk compared with its inorganic sources. This is supported by studies on zinc 
deposition in eggs (Mabe et al., 2003; Huyghebaert et al., 2006; Plaimast et al., 2008; Bahakaim et al., 
2014) and milk (Kirchgessner et al., 1994; Pechova et al., 2006, 2009) carried out on animals fed diets 
supplemented with sources of amino acid chelated with this trace element. Only hepatic zinc 
deposition levels are generally higher after supplementation with organic forms of zinc (EFSA 
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FEEDAP Panel, 2015). This statement is consistent with previous reviews and meta-analyses of data 
from poultry, pigs and ruminants, which concluded that organic and inorganic sources of zinc, in 
general, are equivalent (Ammerman et al., 1998; Jongbloed et al., 2002; Schlegel et al., 2013; EFSA 
FEEDAP Panel, 2014). 
Therefore, the FEEDAP Panel considers that zinc from zinc chelate of L-lysinate-HCl would not result 
in a different zinc deposition in edible tissues/products than the standard inorganic source zinc 
sulphate heptahydrate when supplemented to feed up to the maximum authorised zinc level in the EU. 
The amount of lysine as an essential amino acid released from the dissociation of zinc chelate of L-
lysinate-HCl in the animal body after its oral intake will be limited by the maximum authorised zinc 
level in animal feed and this lysine will be used in protein synthesis and/or metabolised to urea/uric 
acid and carbon dioxide without any modification of edible tissues/products. 
3.2.2. Toxicological studies 
No specific toxicological studies for the product under application were submitted. 
The toxicological properties of zinc have been discussed in detail by the SCF (EC, 2003b). It exerts 
low oral acute toxicity, with high doses (2–8 mg Zn/kg body weight per day in different species) 
resulting in gastrointestinal distress with clinical signs of nausea, vomiting, abdominal cramps and 
diarrhoea. Some positive results were observed in genotoxicity tests. In the opinion of the SCF, the 
weight of evidence from the in vitro and in vivo genotoxicity tests supports the conclusion that zinc, 
notwithstanding some positive findings at chromosome level with elevated doses, has no biologically 
relevant genotoxic activity (reviewed by the World Health Organization (WHO, 2001)). This 
conclusion is supported by the US Agency for Toxic Substances and Disease Registry (ATSDR, 
2005). The toxicology of zinc has been recently reviewed by Nordberg et al. (2015). One of the most 
sensitive and well-described effects of chronic excess of zinc intake is a depressed copper uptake with 
associated copper deficiency effects (reviewed by Maret and Sandstead, 2006). 
3.2.3. Assessment of consumer exposure 
The SCF derived a tolerable upper intake level (UL) of 25 mg Zn/day for adults and of 13 mg Zn/day 
for 7- to 10-year-old children (EC, 2003b). The UL for adults was based on a depressed copper uptake 
and an altered lipid profile in humans. An uncertainty factor of 2 was applied owing to the small 
number of subjects included in relatively short-term studies but acknowledging the rigidly controlled 
metabolic experimental conditions employed. 
Concerning exposure of consumers to zinc, the FEEDAP Panel noted in 2014: “In all consumer 
groups, tissues and products of animal origin contributed to about 40–50 % of total zinc intake, with 
meat and milk being the two main items (Walsh et al., 1994; Mensink et al., 2007; Bundesministerium 
für Ernährung, Landwirtschaft und Verbraucherschutz, 2008). On average, among all consumer 
groups, the contribution of milk and meat to the total zinc intake is nearly the same. The practice of 
supplementing animal feed with zinc-containing compounds has not essentially changed during the 
last decades. It is therefore reasonable to assume that food of animal origin recorded in the above-
mentioned consumption surveys derived from animals fed zinc-supplemented diets” (EFSA FEEDAP 
Panel, 2014). 
Based on bioavailability data of zinc from the product under assessment and considering also 
published scientific literature (see section 3.2.1) on the use of amino acids chelated with zinc, the 
FEEDAP Panel does not expect a modification of consumer exposure to zinc by the use of zinc chelate 
of L-lysinate-HCl in animal nutrition. 
3.2.4. Conclusions on the safety for the consumer 
No concerns for consumer safety are expected from the use of zinc chelate of L-lysinate-HCl as a 
source of zinc in animal nutrition. 
Aminotrace zinc bislysinate for all animal species 
 
EFSA Journal 2015; 13(11):4267 14 
3.3. Safety for the user 
3.3.1. Effects on the respiratory system 
No specific studies have been submitted with the additive under assessment. 
The powder form has a dusting potential of 12.8‒13.5 g/m3, with respirable particles ≤ 10 µm making 
up about 96 % of particles of the dust; considering the theoretical zinc content of the dust (about 14 %, 
according to analytical measurements), the resulting zinc exposure is of about 2 g/m
3
. Granulating the 
zinc chelate of L-lysinate-HCl reduces the dusting potential by a factor of about 10
5
 (0.1 mg/m
3
); 
considering also the virtual absence of particles of respirable size, the inhalation exposure to the 
granulated form of zinc chelate of L-lysinate-HCl is minimal. 
Concerning the guidance values for occupational exposures to zinc compounds, the National Institute 
for Occupational Safety and Health (NIOSH) of the USA reported the following recommended 
exposure limits for zinc oxide dust: 5 mg/m
3
 for a 10-hour time-weighted average, with a maximum of 
15 mg/m
3
 (short-term exposure limit (STEL)) (NIOSH, 1978). The American Conference of 
Governmental Industrial Hygienists (ACGIH) proposed a threshold limit value (TLV) for zinc oxide 
of 2 mg/m
3
 (zinc in respirable fraction) based on metal fume fever as the critical effect (ACGIH, 
2003). The FEEDAP Panel considers it appropriate to use the ACGIH parameters for zinc oxide as the 
most conservative and up-to-date guidance for evaluating the risk upon inhalation exposure of the zinc 
compounds under assessment. On the other hand, the FEEDAP Panel recognises that the use of TLV 
as a guidance value for the user safety of feed additives may result in overly conservative assessments, 
since the exposure is unlikely to be as continuous and intense as in an industrial scenario, for which 
TLVs have been envisaged. Indeed, the actual user exposure to dust from feed additives may be more 
consistent with a short-term, intermittent pattern rather than with a continuous pattern; therefore, the 
use of an up-to-date STEL may be closer to a real-life scenario. 
Even with the above caveats, the estimated zinc concentration in the respirable dust resulting from the 
use of zinc chelate of L-lysinate-HCl (powder form) will exceed the TLV or the STEL by three or two 
orders of magnitude, respectively, indicating a risk by inhalation for users. 
3.3.2. Effects on the eyes and skin 
Good Laboratory Practice-compliant tests were conducted in rabbits for skin irritation (according to 
the Organisation for Economic Co-operation and Development (OECD) Guideline 404)
38
 and eye 
irritation (according to OECD Guideline 405)
39
 with both forms of the additive. 
Both forms of the additive produced reversible skin irritation, which was slight to moderate for the 
powder form and very slight for the granulate form. Both forms of the additive produced serious 
irritation to the eye; for the powder form this reaction was irreversible. 
No skin sensitisation studies were performed. In the absence of specific information, the FEEDAP 
Panel considers it prudent to regard the additive as a potential skin sensitiser. 
3.3.3. Conclusions on the safety for users 
Zinc chelate of L-lysinate-HCl in the powder form poses a risk to users by inhalation, whilst for the 
granulate form that risk is minimised. Neither form, powder or as granulate, is a dermal irritant. Both 
forms are irritant to the eye (following Regulation (EC) No 1272/2008 Category 1 for the powder 
form, and Category 2 for the granulate). In the absence of specific information, the additive should be 
regarded as a potential skin sensitiser. 
                                                     
38 Technical Dossier/Section III/Annex III_3_5 and Annex III_3_7.  
39 Technical Dossier/Section III/Annex III_3_6 and Annex III_3_8 . 
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3.4. Safety for the environment 
The FEEDAP Panel has already considered the potential risks to the environment posed by the use of 
zinc in feedingstuffs up to the maximum authorised contents in the EU (EFSA, 2012b, 2012c, 2012d, 
2012e; EFSA FEEDAP Panel, 2013c, 2014, 2015). The additive under assessment, zinc chelate of L-
lysinate-HCl, is intended to be a substitute for other authorised zinc additives. It will therefore not 
further increase the environmental burden of zinc. 
4. Efficacy 
The applicant provided two trials to demonstrate the efficacy of zinc chelate of L-lysinate-HCl, one 
with chickens for fattening and another one with weaned piglets. In both experiments the efficacy of 
zinc chelate of L-lysinate-HCl was compared to zinc sulphate heptahydrate. 
The applicant submitted a study with chickens for fattening (Ross 308) to support the efficacy of the 
additive. This study could not be considered (see section 3.1.1.2). 
Another study with weaned piglets was provided by the applicant and has been already described in 
the section “Safety for target species” (see section 3.1.1.3). Concerning the bioavailability parameters, 
zinc deposition data for tibia, liver, kidney and pancreas appeared associated to the dietary zinc supply 
(Table 3); there were no significant differences in the deposition in these four tissues between the two 
zinc sources (sulphate and lysinate). 
4.1. Conclusions on efficacy for target species 
In the study in weaned piglets, zinc chelate of L-lysinate-HCl had the same effects in comparison with 
an established zinc source (zinc sulphate heptahydrate). The FEEDAP Panel concludes that zinc 
chelate of L-lysinate-HCl is efficacious as a source of zinc in meeting the requirements of all animal 
species. 
5. Post-market monitoring 
The FEEDAP Panel considers that there is no need for specific requirements for a post-market 
monitoring plan other than those established in the Feed Hygiene Regulation
40
 and Good 
Manufacturing Practice. 
CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS 
Zinc chelate of L-lysinate is a safe source of zinc for all animal species, provided that the maximum 
zinc contents authorised in complete feed are respected. 
No concerns for consumer safety are expected from the use of the zinc chelate of L-lysinate-HCl in 
animal nutrition. 
Zinc chelate of L-lysinate-HCl in the powder form poses a risk to users by inhalation, whilst for the 
granulate form that risk is minimised. Neither form, powder or as granulate, is a dermal irritant. Both 
forms are irritant to the eye. In the absence of specific information, the additive should be regarded as 
a potential skin sensitiser. 
The additive under assessment, zinc chelate of L-lysinate-HCl, is intended to be a substitute for other 
authorised zinc additives. It will therefore not further increase the environmental burden of zinc. 
                                                     
40 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down 
requirements for feed hygiene. OJ L 35, 8.2.2005, p. 1. 
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Zinc chelate of L-lysinate-HCl is efficacious as a source of zinc in meeting the requirements of all 
animal species. 
RECOMMENDATIONS 
In order to avoid confusion with other zinc chelates of lysine containing 1 mol zinc with 1 mol of 
lysine, the FEEDAP Panel recommends “Zinc bislysinate HCl” for the name of the additive under 
assessment. 
The description of the additive should include the zinc and lysine contents. The proposed figures are 
≥ 13.5 % zinc and ≥ 85 % lysine-HCl, for both forms of the additive. 
The lysine content of the additive should be considered when formulating feed for piglets. 
GENERAL REMARK 
The FEEDAP Panel made a proposal to reduce the maximum currently authorised content of zinc in 
feed (EFSA FEEDAP Panel, 2014). The Panel outlines that the conclusions on target animal safety 
and on consumer safety made in the current opinion need not to be modified if the reduced maximum 
content is put into force by legislation. However, the reduction of zinc in feed would lead to a 
beneficial effect on the environment: the zinc load is estimated to decrease by 20 %. 
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ANNEX 
Annex A.  Executive Summary of the Evaluation Report of the European Union Reference 
Laboratory for Feed Additives on the method(s) of analysis for Zinc Chelate of L-Lysinate 
HCl
41
 
In the current application authorisation is sought under article 4(1) for Zinc Chelate of L-Lysinate HCl 
under the category/functional group (3b) “nutritional additives”/”compounds of trace elements”, 
according to the classification system of Annex I of Regulation (EC) No 1831/2003. Specifically, 
authorisation is sought for the use of the feed additive for all categories and species. 
Zinc Chelate of L-Lysinate HCl is a white-grey free flowing powder or granules with a minimum 
content of 13.7 % total zinc and a maximum content of 86.3 % L-Lysine HCl. The feed additive is 
intended to be incorporated into premixtures and feedingstuffs. The Applicant suggested maximum 
levels of total zinc in the feedingstuffs complying to the limits set in Regulation (EC) No 1334/2003, 
ranging from 150 to 250 mg/kg - depending of the animal species/category. 
For the quantification of Lysine content in the feed additive and premixtures the Applicant submitted 
the ring-trial validated method by the “Association of German Agricultural Analytical and Research 
Institutes” (VDLUFA, Germany – Method 4.11.6), based on ion-exchange chromatography coupled 
with post-column derivatisation and colourimetric or fluorescence detection. Furthermore, the EURL 
identified the recently published ring-trial validated method EN ISO 17180:2013 for the 
“determination of Lysine […] in commercial amino acid products and premixtures”, based on ion-
exchange chromatography coupled with post-column derivatisation and colourimetric or fluorescence 
detection. The method does not distinguish between the salts and the amino acid enantiomers and 
applies for the products/premixtures containing more than 10 % of amino acid content. Based on 
acceptable performance characteristics available, the EURL recommends for official control the two 
ring-trial validated methods (VDLUFA 4.11.6 and EN ISO 17180:2013) to quantify Lysine in the feed 
additive and premixtures. 
For the quantification of total Lysine in feedingstuffs the EURL already evaluated and recommended 
in the frame of the Lysine group dossier FAD-2010-0067 the ring-trial validated Community method. 
This method applies for the determination of free (synthetic and natural) and of total (peptide-bound 
and free) amino acids, using an amino acid analyzer or High Performance Liquid Chromatography 
(HPLC) equipment. The method does not distinguish between the salts and the amino acid 
enantiomers. This method was further ring-trial validated, resulting in the EN ISO 13903:2005 
method. 
For the determination of total zinc in the feed additive, premixtures and feedingstuffs the Applicant 
submitted the internationally recognised ring-trial validated method EN 15510 based on inductively 
coupled plasma atomic emission spectroscopy (ICP-AES). Two EURL Evaluation Report “Zinc Chelate 
of L-Lysinate HCl” additional methods were previously evaluated and recommended by the EURL in 
the frame of the Zinc group dossier: the ring-trial validated EN 15621 method based on ICP-AES after 
pressure digestion and the Community method based on atomic absorption spectroscopy. The 
Community method was further ring-trial validated by the UK Food Standards Agency (FSA). Based 
on the acceptable method performance characteristics available, the EURL recommends for official 
control the two CEN methods (EN 15510 or EN 15621) for the quantification of total zinc in the feed 
additive, premixtures and feedingstuffs, together with the Community method (Com Reg (EC) No 
152/2009 – Annex IV-C) for the determination of total zinc in feedingstuffs. 
Further testing or validation of the methods to be performed through the consortium of National 
Reference Laboratories as specified by article 10 (Commission Regulation (EC) No 378/2005) is not 
considered necessary. 
                                                     
41 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/default/files/finrep-fad-2014-0021-zinc-
lysinate.pdf 
